Orbimed Advisors LLC Grows Holdings in Vera Therapeutics, Inc. $VERA

Orbimed Advisors LLC boosted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 4.6% during the first quarter, Holdings Channel.com reports. The fund owned 369,596 shares of the company’s stock after acquiring an additional 16,096 shares during the quarter. Orbimed Advisors LLC’s holdings in Vera Therapeutics were worth $14,869,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in VERA. GAMMA Investing LLC boosted its position in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the period. Optimize Financial Inc increased its stake in shares of Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after purchasing an additional 256 shares in the last quarter. Virtus Investment Advisers LLC raised its position in shares of Vera Therapeutics by 5.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after purchasing an additional 290 shares during the period. Intech Investment Management LLC raised its position in shares of Vera Therapeutics by 2.4% during the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after purchasing an additional 424 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after buying an additional 550 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares in the company, valued at $6,429,346.20. The trade was a 23.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 83,250 shares of company stock valued at $3,337,770. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Stock Performance

Vera Therapeutics stock opened at $35.45 on Monday. Vera Therapeutics, Inc. has a 1 year low of $19.07 and a 1 year high of $56.05. The firm’s 50 day moving average price is $37.00 and its 200-day moving average price is $40.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The stock has a market cap of $2.54 billion, a P/E ratio of -6.40 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the previous year, the company posted ($0.81) EPS. On average, equities analysts predict that Vera Therapeutics, Inc. will post -6.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on VERA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Evercore set a $91.00 price target on Vera Therapeutics in a report on Friday, May 15th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Bank of America upped their price objective on Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Finally, Guggenheim increased their target price on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $84.58.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.